A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

Inclusion Criteria: * male or female, ≥ 6years of age; * who have a diagnosis of allergic asthma ≥ 1 year duration according to American Thoracic Society (ATS) criteria; * severe persistent allergic asthma who remain symptomatic despite optimal therapy (as per Canadian Asthma Consensus Report (1999)); * Subjects having successfully completed one of the following protocols: CIGE025A011E3, CIGE025A2425, CIGE025AIA05; * elevated immunoglobin E levels Exclusion Criteria: * significant systemic disease * pregnancy or lactation * an active lung disease other than allergic asthma (eg: cystic fibrosis, bronchiestasis); * history of food or drug related severe anaphylactoid or anaphylactic reaction(s); * current treatment with warfarin (Coumadin®), immunomodulatory therapy (e.g., methotrexate, gold, cyclosporine), or antiplatelet therapy.